Apogee Therapeutics, Inc. (APGE) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Current obligations | 37.51M USD | Liabilities, Current |
| Cash and equivalents | 105.57M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 866.36M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $37.51M | $105.57M | $866.36M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $32.95M | $451.80M | $608.09M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $27.91M | $131.55M | $598.64M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $34.05M | $107.91M | $419.38M | (m) | (m) | (m) |
| 2025-06-30 | (m) | $31.55M | $124.19M | $381.23M | (m) | (m) | (m) |
| 2025-03-31 | (m) | $32.96M | $106.92M | $406.41M | (m) | (m) | (m) |
| 2024-12-31 | (m) | $28.56M | $141.79M | $378.86M | (m) | (m) | (m) |
| 2024-09-30 | (m) | $32.61M | $118.78M | $407.27M | (m) | (m) | (m) |
| 2024-06-30 | (m) | $24.62M | $307.30M | $368.93M | (m) | (m) | (m) |
| 2024-03-31 | (m) | $21.55M | $485.46M | $330.74M | (m) | (m) | (m) |
| 2023-12-31 | (m) | $20.56M | $118.32M | $277.14M | (m) | (m) | (m) |
| 2023-09-30 | (m) | $17.18M | (m) | $234.59M | (m) | (m) | (m) |
| 2023-06-30 | (m) | $17.61M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | $141.33M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $9.98M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.